Vor Bio Reports First Quarter 2024 Financial Results and Provides Company Update
09 mai 2024 16h05 HE
|
Vor Biopharma
On-track for trem-cel and VCAR33ALLO clinical updates in the second half of 2024Trem-cel trial expanded to include patients with myelodysplastic syndromes (MDS); Mylotarg™ dosing has advanced to the...
Annual NMDP Gala in New York Raises More Than $560,000, Enabling More Patients to Receive Life-Saving Cell Therapy
08 mai 2024 14h46 HE
|
NMDP
The annual NMDP Gala in New York raises critical funds, enabling more patients to receive life-saving cell therapy.
International Myeloma Foundation Holds 15th Annual Gala at the Edison Ballroom in New York City on April 18
25 avr. 2024 08h45 HE
|
International Myeloma Foundation
On April 18, the International Myeloma Foundation held its 15th Annual Gala at the Edison Ballroom for the first time in New York, hosted by Ray Romano.
Lifelong Philanthropist and 17-year Myeloma Survivor John O’Dwyer Elected to the International Myeloma Foundation’s Board of Directors
14 mars 2024 08h45 HE
|
International Myeloma Foundation
STUDIO CITY, Calif. , March 14, 2024 (GLOBE NEWSWIRE) -- The International Myeloma Foundation (IMF) is thrilled to welcome lifelong philanthropist and 17-year myeloma survivor John O’Dwyer to the...
Trace Genomics CEO & Co-Founder Poornima Parameswaran Elected to the International Myeloma Foundation’s Board of Directors
08 févr. 2024 08h45 HE
|
International Myeloma Foundation
Trace Genomics CEO & Co-Founder Poornima Parameswaran Elected to the International Myeloma Foundation’s Board of Directors
Vor Bio Doses First AML Patient with VCAR33 (ALLO) and Provides Corporate Update
17 janv. 2024 16h01 HE
|
Vor Biopharma
First patient dosed in company’s second clinical program with initial data expected in second half of 2024Cash runway extended into second half of 2025 with clinical trials on track CAMBRIDGE, Mass.,...
ExCellThera rencontrera les investisseurs durant la 42e conférence annuelle J.P. Morgan Healthcare et participera aux prochaines conférences d'investisseurs
02 janv. 2024 07h00 HE
|
ExCellThera
MONTREAL, 02 janv. 2024 (GLOBE NEWSWIRE) -- ExCellThera Inc. (ExCellThera), un leader mondial des thérapies à base de cellules souches sanguines amplifiées, a annoncé aujourd'hui que ses hauts...
ExCellThera to Conduct Investor Meetings During the J.P. Morgan 42nd Annual Healthcare Conference and to Participate in Upcoming Investor Conferences
02 janv. 2024 07h00 HE
|
ExCellThera
ExCellThera senior leaders will be holding investor meetings during JP Morgan Heathcare Conference and participating in upcoming investor conferences.
Cell BioEngines Enters Agreement with Miltenyi Bioindustry to Manufacture Hematopoietic Cell Therapy Clinical Program
29 déc. 2023 18h13 HE
|
Cell BioEngines, Inc.
NEW YORK, Dec. 29, 2023 (GLOBE NEWSWIRE) -- Cell BioEngines, Inc., a clinical-stage biotechnology company focused on delivering novel, innovative stem cell and immune cell therapies to address blood...
ExCellThera annonce les résultats positifs des études de phase 2 de la thérapie cellulaire UM171 chez des patients atteints de leucémies et de myélodysplasies à haut risque lors du congrès annuel 2023 de l'American Society of Hematology (ASH)
12 déc. 2023 07h00 HE
|
ExCellThera
- Données présentées lors d'une séance orale à l'ASH 2023, s'appuyant sur des données solides antérieures issues d'une étude de phase 1/2 et d'études comparatives de registres. - La thérapie...